Skip to search formSkip to main contentSkip to account menu

PD 173955

Known as: PD-173955, PD173955 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

PyridonesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Development of Kinase Inactive PD173955 Analogues for Reducing Production of Aβ Peptides.
Compound 3a, DV2-103, is a kinase inactive analogue of a potent Abl1/Src kinase inhibitor, PD173955, 2. Both compounds, 2 and 3a… 
2018
2018
Abstract 1661: Discovery of potent Abelson kinase inhibitors from the scaffold of pyrano[2,3-d]pyrimidin-7-one
Tyrosine kinases regulate cell proliferation, survival, invasion and angiogenesis during tumor initiation and progression. The… 
2017
2017
Chemoproteomics‐Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors
The receptor tyrosine kinase EPHA2 has gained attention as a therapeutic drug target for cancer and infectious diseases. However… 
2010
2010
New effective inhibitors of the Abelson kinase.
2006
2006
Phosphorylation of IkappaB-beta is necessary for neuronal survival.
Cerebellar granule neurons undergo apoptosis when switched from culture medium containing depolarizing levels of potassium (high… 
2006
2006
Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases
MOTIVATION According to the models of divergent molecular evolution, the evolvability of new protein function may depend on the… 
2005
2005
Conformational plasticity in drug design: Towards the development of inhibitors of oncogenic fusion proteins with protein tyrosine kinase activity
BMS354825 is a SRC-Abl dual inhibitor active against several imatinib-resistant Bcr-Abl mutants except T315I. BMS354825 has been… 
Review
2003
Review
2003
Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies
The chronological history of the important discoveries leading to our present understanding of the essential clinical, biological… 
2002
2002
c-Kit Receptor Tyrosine Kinases Characterization of Potent Inhibitors of the Bcr-Abl and the Updated
The early stage of chronic myelogenous leukemia (CML) is caused by the tyrosine kinase Bcr-Abl. Imatinib mesylate (also known as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)